Fourth-quarter and fiscal year end 2009 results announced by Noveko International

Year marked by the strengthening of the group, product and market development and a 63.7% increase in revenues from continuing operations Positive outlook for the current fiscal year

Noveko International Inc. ("the Company") today announces the financial results for its fourth quarter and fiscal year ended June 30, 2009.

"Despite a 63.7% increase in revenues from continuing operations over the previous year, we posted mixed results. However, they reflect the efforts we put into developing our products, distribution networks and group infrastructure by closing strategic acquisitions and adding key personnel, all of which are critical for our long-term growth. These developments required time and the investment of significant human and financial resources, the effects of which were felt all the more as the sales of our antimicrobial products are still only at their beginnings. Furthermore, certain items that affected our results had no impact on our cash position, such as stock-based compensation charge and goodwill impairment related notably to the recent conditions in a subsidiary's market," indicated André Leroux, Chairman of the Board and Chief Executive Officer of the Company.

Financial Highlights for Continuing Operations (BLI's Operating Results Treated as Discontinued Operations)

For the fiscal year and the fourth quarter, in comparison with the corresponding periods of the previous year:

- Consolidated revenues from continuing operations respectively up by 63.7% to $12.2 million, and up by 44.7% to $3.4 million - Loss before amortization, financial expenses, income taxes, other items and discontinued operations - including stock-based compensation - respectively up by $7.6 million and down by $1.6 million - Loss from continuing operations respectively up by $14.8 million and $3.4 million

"The pandemic threat gave us an opportunity to accelerate our growth, paving the way for a promising outlook throughout the current fiscal year and over the longer term. Our expected sales growth will improve our financial performance," added Mr. Leroux. "During the year, we concluded new agreements and partnerships that are already bearing fruit, as attested to by our significant order book for Noveko(TM) antimicrobial face masks and respirators and AZURO(TM) hand sanitizers, also demonstrating the greater interest in our know-how and expertise. In addition, we managed to have our suppliers increase their production capacity in order to meet the growing demand, thereby enabling us to better serve our clients."

"Integrating the acquired entities into our group, and especially pooling our technologies, allowed us to achieve significant breakthroughs in the air filtration segment, notably in the farming sector, although the market deployment of our Noveko antimicrobial air filters was not as rapid as expected, due to the difficult conditions currently prevailing in the swine industry. We are however confident of being well positioned to benefit from an eventual recovery. We also believe that the current fiscal year will be promising in regard to new applications for our air filters in the aeronautics, rail transport and building segments."

"All in all, we have the assets, organizational capabilities and human resources to further develop our primary growth vectors, namely our antimicrobial face masks and respirators, air filtration products, sanitizers and medical equipment," concluded Mr. Leroux.